Multiple myeloma trials in Denmark

In Denmark 26 Also abroad 703

26 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 1Taking people
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
Where
Odense C, Vejle
Age
18 years and over
People
250 worldwide
Run by
AbbVie
See details and how to joinNCT05650632 · EU 2023-504674-38-00
Phase 3Taking people
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
Where
Aarhus N, Copenhagen Oe, Roskilde, Vejle
Age
18 years and over
People
380 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT07555938 · EU 2025-524028-23-00
Phase 3Taking people
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Where
Aalborg, Herning, Næstved, Vejle
Age
18 years and over
People
1,590 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT05552222 · EU 2023-503442-30-00
Phase 3Taking people
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Where
Aarhus N, Copenhagen Oe, Odense C, Roskilde
Age
18 years and over
People
440 worldwide
Run by
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
See details and how to joinNCT06615479 · EU 2024-515279-37-00
Phase 3Taking people
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
Where
Aarhus N, Copenhagen Oe, Odense C, Vejle
Age
18 years and over
People
1,060 worldwide
Run by
Pfizer
See details and how to joinNCT05623020 · EU 2024-514139-50-00
No phaseNot yet taking people in Denmark
Why Patients Decline or Are Being Deemed Ineligible to Receive Home-based Treatment: a Mixed Methods Study
Where
Copenhagen, Odense, Roskilde
Age
18 years to 100 years
People
50
Run by
Odense University Hospital
See details and how to joinNCT07634263
Phase 3Taking people
A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).
Where
Aarhus, København Ø, Odense
Age
18 years to 130 years
People
750 worldwide
Run by
AstraZeneca
See details and how to joinNCT07735637
Phase 1Taking people
A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
Where
Copenhagen Oe
Age
18 years and over
People
186 worldwide
Run by
Genentech, Inc.
See details and how to joinNCT04910568 · EU 2023-507019-36-00
No phaseNot yet taking people in Denmark
Immunoprofiling of the Patient Tumor Microenvironment in BCMA Targeted Therapies
Where
Aarhus, Copenhagen, Gødstrup, Odense, Roskilde, Vejle
Age
18 years and over
People
50 worldwide
Run by
Odense University Hospital
See details and how to joinNCT07878208
Phase 3Taking people
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
Where
Copenhagen, Roskilde, Vejle
Age
18 years and over
People
63 worldwide
Run by
CSL Behring
See details and how to joinNCT07648264 · EU 2026-525626-38-00
Phase 3Taking people
A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
Where
Aalborg, Aarhus N, Copenhagen Oe, Odense C
Age
18 years and over
People
183 worldwide
Run by
Takeda
See details and how to joinNCT06980480 · EU 2024-518420-80-00
Phase 3Not yet taking people in Denmark
A trial to learn how well AZD0120 works and about its safety in adults with transplant eligible newly diagnosed multiple myeloma.
Where
Aarhus N, Copenhagen Oe, Odense C
Age
18 years and over
People
249 worldwide
Run by
AstraZeneca AB
See details and how to join2026-525367-40-00 · EU 2026-525367-40-00
Phase 2Not yet taking people in Denmark
Restrictive Versus Standard Antibiotic Treatment During CAR-T Therapy
Where
Roskilde
Age
18 years and over
People
150
Run by
Zealand University Hospital
See details and how to joinNCT07842198
Phase 3Not yet taking people in Denmark
A trial to learn how well AZD0120 works and about its safety in adults with newly diagnosed multiple myeloma
Where
Aarhus N
Age
18 years and over
People
234 worldwide
Run by
AstraZeneca AB
See details and how to join2025-524014-29-00 · EU 2025-524014-29-00
No phaseTaking people
A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials
Where
Aalborg, Aarhus N, Copenhagen, Odense, Vejle
Age
18 years and over
People
900 worldwide
Run by
Janssen-Cilag Ltd.
See details and how to joinNCT06285318
Phase 3Taking people
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Where
Aalborg, Aarhus N, Copenhagen Oe
Age
18 years and over
People
492 worldwide
Run by
Pfizer
See details and how to joinNCT06152575 · EU 2023-507871-23-00
Phase 3Taking people
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
Where
Århus N
Age
18 years and over
People
750 worldwide
Run by
AstraZeneca
See details and how to joinNCT07764978
No phaseTaking people
Compassionate Communication and Advance Care Planning to Improve End of Life Care in Treatment of Hematological Disease (ACT)
Where
Aalborg, Aarhus, Esbjerg, Herning, Odense, Roskilde, Vejle
Age
18 years and over
People
920
Run by
Christoffer Johansen
See details and how to joinNCT05444348
Phase 2Not yet taking people in Denmark
Teclistamab in Combination With Pomalidomide Administered in Alternative Fashion in Participants With Relapsed or Refractory Multiple Myeloma.
Where
Aarhus N, Odense C
Age
18 years and over
People
50 worldwide
Run by
Odense University Hospital
See details and how to joinNCT07757412 · EU 2025-522114-23-00
Phase 1Taking people
A Study in Leukemia Patients With Karonudib
Where
Aarhus, Copenhagen
Age
18 years to 75 years
People
50 worldwide
Run by
Thomas Helleday Foundation
See details and how to joinNCT04077307
No phaseNot yet taking people in Denmark
Cognitive Impairment in Patients Undergoing Cell- and Antibody-based Immunotherapies for Haematological Malignancies: The COGNITOX Study
Where
Aarhus
Age
18 years and over
People
225
Run by
Aarhus University Hospital
See details and how to joinNCT07558057
Phase 3Taking people
A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant
Where
Aarhus N, Roskilde
Age
18 years and over
People
1,000 worldwide
Run by
European Myeloma Network B.V.
See details and how to joinNCT06932562 · EU 2024-519827-16-00
Phase 4Not yet taking people in Denmark
BLOOD-dose: A Platform Trial Evaluating Dose Optimization in Hematological Diseases.
Where
Aalborg, Aarhus, Copenhagen, Odense, Roskilde
Age
18 years and over
People
400
Run by
Anne Louise Tølbøll Sørensen
See details and how to joinNCT07474961 · EU 2026-525658-13-00
Phase 2Taking people
Self-administration of Subcutaneous Elranatamab in the Patients' Homes.
Where
Odense C, Vejle
Age
18 years and over
People
20
Run by
Thomas Lund
See details and how to joinNCT06015542 · EU 2023-507876-30-00
No phaseTaking people
Examination of Vertebroplasty in Addition to Regular Treatment of Patients With Multiple Myeloma.
Where
Middelfart
Age
18 years and over
People
90
Run by
Spine Centre of Southern Denmark
See details and how to joinNCT04533217